Scientific Surgery Online Journals

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Scientific Surgery

Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials. J Clin Med. 2020; 9: 1129.

Authors: Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A et al.

Scientific Surgery

FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406.

Authors: Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul J-L et al.

Scientific Surgery

Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg 2018; 268: 215-222.

Authors: Jang J-Y, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H et al.

Scientific Surgery

CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 2017; 35: 3330-3337.

Authors: Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W et al.

Scientific Surgery

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011–24.

Authors: Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al.

Scientific Surgery

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248–25716.

Authors: Uesaka K, Boku N, Kukutomi A, Okamura Y, Knoishi M, Matsumoto I et al.

Scientific Surgery

Adjuvant chemotherapy with gemcitabine and long term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481.

Authors: Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K et al. et al.

Scientific Surgery

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308: 147–156.

Authors: Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC et al. et al.

Scientific Surgery

Open-label, multicentre, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012; 30: 4077–4083.

Authors: Schmidt J, Abel U, Debus J, Harig S, Hoffman K, Herrmann T et al. et al.

Scientific Surgery

Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World J Surg 2012; 36: 1016-1029.

Authors: Coughlin S, Roth L, Lurati G, Faulhaber M

Scientific Surgery

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105–4112.

Authors: Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D et al.

Scientific Surgery

Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29: 3541–3546.

Authors: Wyse JM, Carone M, Paquin SC, Usatill M, Sahai AV

Scientific Surgery

Adjuvant chemotherapy with fluorouracil plus folinic acid versus gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081.

Authors: Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al. et al.

Scientific Surgery

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7: e1000267.

Authors: Gillen S, Schuster T, Buschenfelde CM, Friess H, Kleef J.

Scientific Surgery

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785.

Authors: Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E et al. et al.

Scientific Surgery

Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-5518.

Authors: Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W et al. et al.

Scientific Surgery

Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomised controlled trial Ann Surg 2008; 248: 1031¿1041

Authors: Morak MJM, van der Gaast A, Incrocci L, van Dekken H, Hermans JJ, Jeekel J et al et al.

Scientific Surgery

Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial Surg Today 2008; 38: 1021-1028

Authors: Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K et al et al.

Scientific Surgery

Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA 2008; 299: 1019-1026.

Authors: Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al.

Scientific Surgery

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008; 371: 2101-2108.

Authors: Spano J-P, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C et al. et al.

Scientific Surgery

Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277.

Authors: Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al.

Scientific Surgery

Long term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long term results of EORTC Trial 40891. Ann Surg 2007; 246: 734-740.

Authors: Smeenk HG, van Eijck CHJ, Hop WC, Erdmann J, Tran KCK, Debois M et al.

Scientific Surgery

A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer Surgery 2004; 136: 1003-1011.

Authors: Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M et al. et al.

Scientific Surgery

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.

Authors: Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al.

Scientific Surgery

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’ Italia Meridionale. Cancer 2002; 94: 902-10.

Authors: Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabbitti P, Uomo G et al. et al.

Scientific Surgery

Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 2002; 236: 806-13.

Authors: Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S.

Scientific Surgery

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-85.

Authors: Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H et al.

Scientific Surgery

Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-68.

Authors: Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P et al. et al.

Scientific Surgery

Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcarcioma. Br J Surg 2001; 88: 662-8.

Authors: Johnson CD, Puntis M, Davidson N, Todd S, Bryce R.

Scientific Surgery

The effects of supplementation with alpha tocopherol and beta carotine on the incidence and mortality of carcinoma of the pancreas in a randomized controlled trial. Cancer 1999; 86: 37-42.

Authors: Rautalahti MT, Virtamo JR, Taylor PR, Heinonen OP, Albanes D, Haukka JK et al. et al.

Older Entries